References
- Zhao B, Li L, Lei Q, et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24:862–874.
- Zhao B, Tumaneng K, Guan K-L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13:877–883.
- Harvey K, Tapon N. The Salvador–Warts–Hippo pathway — an emerging tumor-suppressor network. Nat Rev Cancer. 2007;7:182–191.
- Santucci M, Vignudelli T, Ferrari S, et al. The Hippo pathway and YAP/TAZ-TEAD protein-protein interaction as targets for regenerative medicine and cancer treatment. J Med Chem. 2015;58:4857–4873.
- Ni L, Zheng Y, Hara M, et al. Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling. Genes Dev. 2015;29:1416–1431.
- Yin F, Yu J, Zheng Y, et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154:1342–1355.
- Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133.
- Lai D, Ho KC, Hao Y, et al. Taxol resistance in breast cancer cells is mediated by the Hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011;71:2728–2738.
- Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147:759–772.
- Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19:491–505.
- Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29:783–803.
- Lei Q-Y, Zhang H, Zhao B, et al. Taz promotes cell proliferation and epithelial-mesenchyamal transition and is inhibited by the Hippo pathway. Mol Cell Bio. 2008;28:2426–2436.
- Xu N, Wu M-Z, Deng X-T, et al. Inhibition of YAP/TAZ activity in spinal cord suppresses neuropathic pain. J Neurosci. 2016;36:10128–10140.
- Liu F, Lagares D, Choi KM, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2015;308:344–357.
- Moroishi T, Hayashi T, Pan -W-W, et al. The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell. 2016;167:1525–1539.
- Miao J, Hsu P-C, Yang Y-L, et al. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget. 2017;8:114576–114587.
- Feichtinger M, Sára T, Platzer G, et al. 1H, 13C, 15N resonance assignment of human YAP 50–171 fragment. Biomol NMR Assign. 2018;6:1–4.
- Wang C, Zhu X, Feng W, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res. 2016;6:27–37.
- Li Z, Zhao B, Wang P, et al. Structural insights into the YAP and TEAD complex. Genes Dev. 2010;24:235–240.
- Gibault F, Sturbaut M, Bailly F, et al. Targeting transcriptional enhanced associate domains (TEADs). J Med Chem. 2017;61:5057–5072
- Holden JK, Cunningham CN. Targeting the Hippo pathway and cancer through the TEAD family of transcription factors. Cancers (Basel). 2018;10:81–96.
- Lin KC, Moroishi T, Meng Z, et al. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat Cell Biol. 2017;19:996–1002.
- Mesrouze Y, Bokhovchuk F, Meyerhofer M, et al. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD. eLife. 2017;6:5147.
- Zhou Z, Hu T, Xu Z, et al. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J. 2014;29:724–732.
- Zhang Z, Lin Z, Zhou Z, et al. Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP–TEAD protein–protein interaction. ACS Med Chem Lett. 2014;5:993–998.
- Noland CL, Gierke S, Schnier PD, et al. Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling. Structure. 2016;24:179–186.
- Chan P, Han X, Zheng B, et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat Chem Biol. 2016;12:282–289.
- Mesrouze Y, Meyerhofer M, Bokhovchuk F, et al. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ. Protein Sci. 2017;26:2399–2409.
- Pobbati AV, Han X, Hung AW, et al. Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure. 2015;23:2076–2086.
- Inventiva website. [cited 2018 Mar 26]. Available from: http://www.inventivapharma.com/
- Soude A, Barth M, Bocart S, et al. Presented at AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics, Boston, MA, November 5–9, 2015. [cited 2018 Mar 26]. Inventiva Website http://www.inventivapharma.com/?q=en/node/97
- Inventiva. New compounds inhibitors of the Yap/Taz-Tead interaction and their use in the treatment of malignant mesothelioma. WO201764277; 2017
- U.S. News & World Report Announces the 2016–2017 Best Hospitals. [cited 2017 Sept 3]. Available from: https://www.usnews.com/info/blogs/press-room/articles/2016-08-02/us-news-announces-the-201617-best-hospitals
- The Massachusetts General Hospital Research Institute by the Numbers. [cited 2017 Sept 3]. Available from: http://www.massgeneral.org/research/about/facts.aspx
- The General Hospital Corporation. TEAD transcription factor autopalmitoylation inhibitors. WO2017053706; 2017
- Chan PY, Han X, Zheng B, et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of hippo pathway. Nat Chem Biol. 2016;12:282–289.